Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GSII - GENERAL SURGICAL INNOVATIONS, INC. -- Ignore unavailable to you. Want to Upgrade?

To: Lighthouse who wrote (162)	2/1/1999 8:05:00 AM
From: Epics	Respond to of 211

I'd hope GSII knows this. From Guidant's point of view, why not take the cash offer a equitable premium given its over priced stock, and move on..I think it will happen because as you said building a sales force is the biggest mistake GSII can make. The powerhouses are just too big, they should just sign distribution agreements with the biggies, they own the technology. It is a 60 Million dollar biz, so GSII does have a good thing. Its the question of will they take advantage of it. 1.5 M (minimum probaly much more considering GDT I believe can no longer sell the product) to each quarter plus cutting needless expenses (i.e sales force eith rev's under 1 million) could turn them into a profitable company and i would hope a trip to the 8-9 area. But there is a word called execution. Im expecting a news release in the next month regarding the trial. Im expecting a settlement with GDT. I could be wrong however

To: Lighthouse who wrote (162)	2/2/1999 5:07:00 PM
From: Epics	Read Replies (1) \| Respond to of 211

GDT having ligigation with another firm, they took them over and took a charge.. GSII up 1/2 in late trading.. hmm.. maybe? 02/02 3:28P (DJ) =Media Barred From Guidant Presentation At N.Y. Conference After completing the acquisition of Sulzer Medica's electrophysiology business Monday, Guidant announced earlier Tuesday that it will post a first quarter pretax charge of $49 million related to the deal. The charge represents the value ascribed to in-process technology, the company said in a press release. Guidant had previously charged its third quarter in 1998 with $200 million of the purchase price ascribed to settlement of intellectual property litigation. Also Tuesday, Guidant said discussions are underway with parties interested in the purchase of Osypka and Oscor, both parts of Sulzer's electrophysiology business. The products made by Osypka and Oscor are not part of Guidant's long-term CRM strategy, the company said. Shares of Guidant were recently trading at 53 15/16, down 4 7/16, or 7.6%. Guidant last week reported 1998 earnings of $43.8 million, or 14 cents a diluted share including charges. Excluding charges, net income was $359.4 million, or $1.19 a diluted share. Sales in 1998 totaled $1.9 billion.